The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000633381
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
6/05/2026
Date registered
Help: Date registered
26/05/2026
Date last updated
Help: Date last updated
28/08/2026
Date data sharing statement initially provided
Help: Data sharing statement date
26/05/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Rest and readiness: What is the optimal nap length during night shifts to improve productivity, performance and safety?
Scientific title
Rest and readiness: Investigating the optimal nap length during night shifts in healthy adults for whole of shift productivity, performance and safety in shift workers.
Additional trial identifiers [1] 317052 0
Project ID: DP250100937
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Fatigue 341565 0
Impaired cognitive performance 342038 0
Condition category
Condition code
Public Health 337692 337692 0 0
Other public health
Neurological 338010 338010 0 0
Studies of the normal brain and nervous system

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Arm 1: 15 minute nap condition
Intervention: Participants are assigned to a 15 min nap opportunity during a scheduled break, within a 12-hour simulated night shift protocol.

Who delivers it and their relevant expertise: The research is delivered by a research team with extensive expertise in sleep and fatigue research. There will be one postdoctoral research fellow, two PhD candidates and trained research assistants conducting the data collection.

How is it delivered: The study is conducted in a controlled sleep laboratory. Participants are assigned to individual bedrooms within a six-bedroom sleep laboratory facility.

How often and for how long: Each experimental condition lasts 40 hours and includes one adaptation night and the following night is a 12-hour simulated night shift where cognitive test batteries and simulated work tasks will be completed throughout the shift. Participants reside in the laboratory for the duration of each condition. The study uses a randomised counterbalanced design with a 5–7-day washout period between conditions.

Where is it delivered: A state of the art six-bedroom sleep laboratory facility.

Adherence: Participants are continuously monitored during laboratory stays. Between experimental conditions, adherence is supported through sleep diaries, food diaries and actigraphy monitoring.

Arm 2: 30-minute nap condition
Intervention: Intervention: Participants are assigned to a 30 min nap opportunity during a scheduled break, within a 12-hour simulated night shift protocol.

(All other components are identical to Arm 1)

Arm 3: 60-minute nap condition
Intervention: Intervention: Participants are assigned to a 60 min nap opportunity during a scheduled break, within a 12-hour simulated night shift protocol.

(All other components are identical to Arm 1)
Intervention code [1] 333847 0
Treatment: Other
Description of the comparator or control
Arm 4: Control condition (no nap)
What is the comparator: The comparator is a no-nap control condition during a 12-hour simulated night shift. Participants remain awake during this scheduled period but continue to complete simulated work tasks. This condition represents wakefulness and is a comparison against the three nap intervention conditions (15, 30 and 60 min nap).

Who delivers it and their relevant expertise: The research is delivered by a research team with extensive expertise in sleep and fatigue research. There will be one postdoctoral research fellow, two PhD candidates and trained research assistants conducting the data collection.

How it is delivered: The condition is delivered individually in a controlled sleep laboratory setting. Participants are assigned to individual bedrooms within a six-bedroom sleep facility and will remain in their bedroom during this scheduled period. They will complete simulated work tasks under supervision to assess whole of shift productivity and safety.

How often and for how long? The comparator condition is implemented over a 40-hour protocol, comprising of 2 consecutive nights, one being an adaptation night and the second a simulated night shift. Participants reside in the laboratory for the full duration of each experimental condition.

Where is it delivered: A purpose built six-bedroom sleep laboratory facility.

Adherence: Participants are continuously monitored during their time in the laboratory by research staff. From 01:00-02:00 where participants remain awake, they will be supervised by researchers. Compliance is support through actigraphy monitoring. Between conditions, participants complete sleep and food diaries as part of the protocol monitoring.
Control group
Active

Outcomes
Primary outcome [1] 345176 0
Cognitive performance
Timepoint [1] 345176 0
Cognitive performance will be assessed repeatedly across the 12-hour simulated shift, with measures taken every 2 hours.
Secondary outcome [1] 460765 0
Sleepiness
Timepoint [1] 460765 0
This measure will be collected at 2-hourly timepoints, prior to the psychomotor vigilance test, across the 12-hour simulated night shift.
Secondary outcome [2] 461657 0
Fatigue
Timepoint [2] 461657 0
This measure will be collected at 2-hourly timepoints following the KSS and prior to the psychomotor vigilance test, across the 12-hour simulated night shift.

Eligibility
Key inclusion criteria
- Healthy participants aged 18-40 years.
- Male or female
- Body Mass Index (BMI) between 18.00-29.99 kg/m2
- Intermediate chronotype (determined by the Morningness/Eveningness questionnaire score)
- No diagnosed sleep disorders
- Not taking medication known to impact sleep
Minimum age
18 Years
Maximum age
40 Years
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
- Smoker
- Use of recreational drugs
- Currently taking prescription drugs that impact sleep
- Pittsburgh Sleep Quality Index score > 5.
- Epworth Sleepiness Scale score > 10
- Insomnia Severity Index score > 15
- Trans meridian travel (> 2 time zones) or shiftwork in the last 3 months.
- > 2 alcohol beverages per day
- Daily caffeine consumption > 400 mg
- > 2 positive responses on Berlin Sleep Questionnaire
- Extreme chronotype (determined by the Morningness/Eveningness questionnaire score)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Off-site allocation
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software (i.e. computerised sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA

Funding & Sponsors
Funding source category [1] 321638 0
Government body
Name [1] 321638 0
Australian Research Council
Country [1] 321638 0
Australia
Primary sponsor type
University
Name
Central Queensland University
Address
Country
Australia
Secondary sponsor category [1] 324620 0
None
Name [1] 324620 0
Address [1] 324620 0
Country [1] 324620 0
Other collaborator category [1] 283927 0
Individual
Name [1] 283927 0
Professor Paul D. Patterson from University of Pittsburgh
Address [1] 283927 0
Country [1] 283927 0
United States of America
Other collaborator category [2] 283928 0
Individual
Name [2] 283928 0
Associate Professor Philip Tucker from Swansea University
Address [2] 283928 0
Country [2] 283928 0
United Kingdom
Other collaborator category [3] 283929 0
Individual
Name [3] 283929 0
Professor John Axelsson from Karolinska Institutet
Address [3] 283929 0
Country [3] 283929 0
Sweden

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320160 0
CQ University's Human Research Ethics Committee
Ethics committee address [1] 320160 0
Ethics committee country [1] 320160 0
Australia
Date submitted for ethics approval [1] 320160 0
10/06/2025
Approval date [1] 320160 0
22/07/2025
Ethics approval number [1] 320160 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149646 0
A/Prof Grace Elizabeth Vincent
Address 149646 0
Appleton Institute, Central Queensland University, 44 Greenhill Rd, Wayville, South Australia, 5034
Country 149646 0
Australia
Phone 149646 0
+61 8 8378 4518
Fax 149646 0
Email 149646 0
Contact person for public queries
Name 149647 0
Grace Elizabeth Vincent
Address 149647 0
Appleton Institute, Central Queensland University, 44 Greenhill Rd, Wayville, South Australia, 5034
Country 149647 0
Australia
Phone 149647 0
+61 8 8378 4518
Fax 149647 0
Email 149647 0
Contact person for scientific queries
Name 149648 0
Grace Elizabeth Vincent
Address 149648 0
Appleton Institute, Central Queensland University, 44 Greenhill Rd, Wayville, South Australia, 5034
Country 149648 0
Australia
Phone 149648 0
+61 8 8378 4518
Fax 149648 0
Email 149648 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires a scientifically sound proposal or protocol
• Requires approval by an ethics committee
What individual participant data might be shared?
• De-identified individual participant data:
• All outcomes data
• Primary outcome(s)
What types of analyses could be done with individual participant data?
• Systematic reviews and meta-analyses
• Studies exploring new research questions
• Studies testing whether findings can be repeated or confirmed
• Teaching research methods or developing new statistical techniques
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
No end date
Where can requests to access individual participant data be made, or data be obtained directly?
• Journal publication or its supplementary materials: Study datasets may be available as supplementary materials accompanying the peer-reviewed journal publication or through the journals data availability statement.

• Email of trial custodian, sponsor or committee: Request for access to participant data can be made by contacting the study sponsor via email ([email protected]). Requests will be assessed on a case by case basis.

Are there extra considerations when requesting access to individual participant data?
Yes: Access may be subject to ethical approval, data use agreements, privacy restrictions, and approval by the study sponsor. Only de-identified data will be shared, and use must be consistent with participant consent and regulations.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.